(“IQ-AI” or the “Company”)
Exercise of Options
IQ-AI Ltd, the parent company of StoneChecker® and Imaging Biometrics®, announces that it has issued 1,000,000 ordinary shares in the Company of par value £0.01 (“Ordinary Shares”) following the exercise of options (“Options”) over Ordinary Shares as summarised below.
The Options have been exercised by David Smith. Mr Smith’s contract as CEO of StoneChecker and Imaging Biometrics, the Company’s subsidiaries, expired on 31st December 2019. Mr Smith is now a consultant to the Company.
The Options were issued as part of David Smith’s employment contract. He has exercised 1,000,000 Ordinary Shares at £0.026 each, totalling £26,000 cash.
Admission and Total Voting Rights
Pursuant to the exercise of the Options, application will be made for 1,000,000 new Ordinary Shares, which will rank pari passu with existing Ordinary Shares, to be admitted to the standard segment of the Main Market (‘Admission’). It is expected that Admission will become effective and dealings will commence at 8:00am on or around 16 January 2020.
Following Admission, the total issued share capital of the Company will consist of 140,830,982 Ordinary Shares. As such, the total number of voting rights in the Company will be 140,830,982 Ordinary Shares. This number may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest in, the Company under the FCA’s Disclosure and Transparency Rules.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.
The Directors of the Company accept responsibility for the contents of this announcement.
For further information, please contact:
Trevor Brown/Vinod Kaushal/Qu Li
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
About IQ-AI Ltd
IQ-AI, Ltd, the parent company of StoneChecker® and Imaging Biometrics®, is focused on advanced and state of the art medical software and services. (IQ-AI.ltd). Imaging Biometrics develops and provides visualization and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB’s advanced visualization software seamlessly integrates into routine workflows. Please visit www.imagingbiometrics.com for further information.